Skip to main content

Table 3 Associations between significant pathways and AJCC stage

From: Improved survival among colon cancer patients with increased differentially expressed pathways

  

Stage 1

Stage 2

Stage 3

Stage 4

 

Pathway

# Features (Genes)

Mean 1

STD

Mean

STD

Mean

STD

Mean

STD

P value 2

Cell Cycle Control of Chromosomal Replication

15

31.0

9.4

30.5

8.8

30.1

7.4

27.0

8.6

0.11

Estrogen-mediated S-phase Entry

13

27.1

7.7

26.2

6.8

26.2

5.8

23.3

6.9

0.06

Thyroid Hormone Metabolism II

12

24.3

5.5

24.3

5.5

24.7

5.7

22.8

5.6

0.33

Hepatic Fibrosis/Hepatic Stellate Cell Activation

39

78.4

14.0

78.5

13.1

80.7

14.1

73.1

14.3

0.17

Cell Cycle: G1/S Checkpoint Regulation

19

38.8

10.4

38.2

9.7

38.6

8.3

34.6

9.7

0.13

Melatonin Degradation I

16

32.1

6.7

32.7

6.7

32.6

6.8

30.7

7.1

0.45

Serotonin Degradation

17

34.7

7.3

34.5

7.1

34.8

7.7

32.5

7.5

0.28

Superpathway of Melatonin Degradation

16

32.1

6.7

32.7

6.7

32.6

6.8

30.7

7.1

0.45

Cyclins and Cell Cycle Regulation

20

41.2

10.9

40.3

10.1

40.4

8.6

36.3

9.9

0.09

Cell Cycle: G2/M DNA Damage Checkpoint Regulation

15

31.2

9.8

30.1

8.7

30.0

7.9

26.8

9.0

0.09

GADD45 Signaling

9

18.9

5.6

18.3

5.2

17.8

4.4

16.4

5.2

0.11

Mismatch Repair in Eukaryotes

8

16.9

4.8

16.2

4.6

15.9

4.1

14.4

5.1

0.06

Mitotic Roles of Polo-Like Kinase

17

35.5

9.6

34.6

9.0

34.0

8.0

30.9

8.6

0.07

Agranulocyte Adhesion and Diapedesis

34

70.6

11.4

68.3

9.8

70.5

11.2

65.6

13.3

0.13

Hereditary Breast Cancer Signaling

24

50.1

13.9

48.7

13.3

48.2

12.2

43.9

13.4

0.10

Granulocyte Adhesion and Diapedesis

32

66.3

10.6

64.8

9.5

66.8

10.6

61.3

12.6

0.10

Nicotine Degradation III

13

25.8

5.9

26.8

5.9

26.3

5.9

24.9

6.2

0.59

Nicotine Degradation II

14

27.8

6.2

28.8

6.4

28.2

6.4

26.9

6.6

0.59

p53 Signaling

20

40.8

11.2

40.6

10.4

40.7

9.7

36.4

11.0

0.15

Axonal Guidance Signaling

60

121.2

20.6

121.9

20.7

122.5

21.1

113.5

22.9

0.18

Aryl Hydrocarbon Receptor Signaling

25

51.4

13.5

50.1

11.6

50.6

10.7

46.3

12.8

0.16

Role of BRCA1 in DNA Damage Response

14

29.5

8.2

28.6

7.7

27.9

7.3

25.2

7.9

0.05

ATM Signaling

13

27.1

7.5

26.6

7.1

25.6

6.3

23.8

7.0

0.10

Complement System

10

20.7

3.3

19.7

3.4

20.3

3.4

19.3

3.6

0.12

Superpathway of Serine and Glycine Biosynthesis I

4

8.1

2.3

8.0

2.3

8.2

2.0

7.5

2.6

0.34

Atherosclerosis Signaling

20

40.4

6.9

39.9

6.1

41.7

6.7

38.4

8.1

0.32

Role of CHK Proteins in Cell Cycle Checkpoint Control

12

25.0

6.8

24.5

6.4

24.0

5.4

21.4

6.4

0.05

RAN Signaling

6

12.6

4.1

11.8

3.7

12.1

3.4

11.0

4.0

0.15

Purine Nucleotides De Novo Biosynthesis II

5

10.2

3.3

10.0

3.1

10.2

3.0

9.2

3.2

0.26

Eicosanoid Signaling

13

26.1

4.0

26.1

4.3

27.0

4.7

25.0

5.0

0.37

Wnt/ß-catenin Signaling

26

52.7

10.6

52.3

9.5

53.2

10.0

48.9

10.9

0.19

  1. 1Mean and SD values are from Differential Pathway Expression Score; 2P values compares differences between Stages 1 and 4.